The false-positive rate of EBV-associated antibody testing limits the effectiveness of nasopharyngeal cancer screening and may have only limited value in screening patients with early-stage disease or in predicting cancer progression in those with elevated IgA antibodies (Ji et al., 2014). Here, CD79A is linked to cancer.